中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2014年
36期
2844-2846
,共3页
肥胖症%神经肌肉阻滞%麻醉
肥胖癥%神經肌肉阻滯%痳醉
비반증%신경기육조체%마취
Obese%Neuromuscular block%Anesthesia
目的:观察丙泊酚全静脉麻醉时肥胖患者按实际体质量给予顺苯磺酸阿曲库铵的神经肌肉阻滞效应。方法选择北京大学第一医院2012年7至12月择期全麻手术患者36例,美国麻醉学会体格分级(ASA)Ⅰ~Ⅱ级,年龄18~65岁,按照体质指数(BMI)将患者分为2组(n=18):肥胖组(BMI>28)和正常体质量组(BMI<24)。2组患者以丙泊酚血浆靶浓度3μg/ml和瑞芬太尼效应室浓度3~5 ng/ml靶控输注诱导,待患者意识消失后给予顺苯磺酸阿曲库铵0.2 mg/kg。使用TOF-Watch SX肌松监测仪,采用单次颤搐刺激(频率0.1 Hz,刺激持续时间0.2 ms),测定刺激前臂尺神经拇内收肌的加速度。记录起效时间、肌颤搐最大抑制程度、临床作用时间、恢复指数和75%恢复时间。肌颤搐抑制达到最大抑制时行气管插管,机械通气,评价气管插管条件。结果肥胖组和正常体质量组平均起效时间分别为(164±25)、(201±48)s,差异有统计学意义(t=2.83,P<0.05),临床作用时间分别为(68.4±9.6)、(62.0±6.5)min,差异有统计学意义(t=2.33,P<0.05),恢复指数分别为(15.6±4.7)、(10.8±4.2)min,差异有统计学意义(t=3.03,P<0.05),75%恢复时间分别为(83.9±11.5)、(73.0±9.2)min,差异有统计学意义(t=2.94,P<0.05)。2组患者气管插管条件优良率均为100%。结论和正常体质量组比较,肥胖患者按实际体质量给予0.2 mg/kg顺苯磺酸阿曲库铵起效时间缩短,临床作用时间和恢复指数延长。
目的:觀察丙泊酚全靜脈痳醉時肥胖患者按實際體質量給予順苯磺痠阿麯庫銨的神經肌肉阻滯效應。方法選擇北京大學第一醫院2012年7至12月擇期全痳手術患者36例,美國痳醉學會體格分級(ASA)Ⅰ~Ⅱ級,年齡18~65歲,按照體質指數(BMI)將患者分為2組(n=18):肥胖組(BMI>28)和正常體質量組(BMI<24)。2組患者以丙泊酚血漿靶濃度3μg/ml和瑞芬太尼效應室濃度3~5 ng/ml靶控輸註誘導,待患者意識消失後給予順苯磺痠阿麯庫銨0.2 mg/kg。使用TOF-Watch SX肌鬆鑑測儀,採用單次顫搐刺激(頻率0.1 Hz,刺激持續時間0.2 ms),測定刺激前臂呎神經拇內收肌的加速度。記錄起效時間、肌顫搐最大抑製程度、臨床作用時間、恢複指數和75%恢複時間。肌顫搐抑製達到最大抑製時行氣管插管,機械通氣,評價氣管插管條件。結果肥胖組和正常體質量組平均起效時間分彆為(164±25)、(201±48)s,差異有統計學意義(t=2.83,P<0.05),臨床作用時間分彆為(68.4±9.6)、(62.0±6.5)min,差異有統計學意義(t=2.33,P<0.05),恢複指數分彆為(15.6±4.7)、(10.8±4.2)min,差異有統計學意義(t=3.03,P<0.05),75%恢複時間分彆為(83.9±11.5)、(73.0±9.2)min,差異有統計學意義(t=2.94,P<0.05)。2組患者氣管插管條件優良率均為100%。結論和正常體質量組比較,肥胖患者按實際體質量給予0.2 mg/kg順苯磺痠阿麯庫銨起效時間縮短,臨床作用時間和恢複指數延長。
목적:관찰병박분전정맥마취시비반환자안실제체질량급여순분광산아곡고안적신경기육조체효응。방법선택북경대학제일의원2012년7지12월택기전마수술환자36례,미국마취학회체격분급(ASA)Ⅰ~Ⅱ급,년령18~65세,안조체질지수(BMI)장환자분위2조(n=18):비반조(BMI>28)화정상체질량조(BMI<24)。2조환자이병박분혈장파농도3μg/ml화서분태니효응실농도3~5 ng/ml파공수주유도,대환자의식소실후급여순분광산아곡고안0.2 mg/kg。사용TOF-Watch SX기송감측의,채용단차전휵자격(빈솔0.1 Hz,자격지속시간0.2 ms),측정자격전비척신경무내수기적가속도。기록기효시간、기전휵최대억제정도、림상작용시간、회복지수화75%회복시간。기전휵억제체도최대억제시행기관삽관,궤계통기,평개기관삽관조건。결과비반조화정상체질량조평균기효시간분별위(164±25)、(201±48)s,차이유통계학의의(t=2.83,P<0.05),림상작용시간분별위(68.4±9.6)、(62.0±6.5)min,차이유통계학의의(t=2.33,P<0.05),회복지수분별위(15.6±4.7)、(10.8±4.2)min,차이유통계학의의(t=3.03,P<0.05),75%회복시간분별위(83.9±11.5)、(73.0±9.2)min,차이유통계학의의(t=2.94,P<0.05)。2조환자기관삽관조건우량솔균위100%。결론화정상체질량조비교,비반환자안실제체질량급여0.2 mg/kg순분광산아곡고안기효시간축단,림상작용시간화회복지수연장。
Objective To explore the neuromuscular effects of cisatracurium besylate in morbidly obese patients when dosed according to real body weight under total intravenous anesthesia with propofol .Methods Thirty-six ASA Ⅰ -Ⅱ patients aged 18 -65 years scheduled for elective procedures at our hospital during July 2012 to December 2012 were allocated into 2 groups according to body mass index ( normal weight:body mass index: <24, overweight:body mass index >28).Anesthesia was induced with target-controlled infusion of propofol ( Cp 3 μg/ml ) and remifentanil ( Ce 3 -5 ng/ml ).A bolus of cisatracurium 0.2 mg/kg was administered intravenously over 5 -10 s as soon as a patient lost consciousness.Neuromuscular block was monitored with TOF-Watch SX ( Oaganon, the Netherlands ).Single stimulation ( 0.1 Hz ) was applied to ulnar nerve at wrist.The maximal degree of neuromuscular block, onset time, clinical duration and recovery index were recorded.They were intubated and mechanically ventilated when neuromuscular block reached the maximal degree.The intubation condition was evaluated.Results The average onset time was (164 ±25) s in obese group versus (201 ±48) s in normal weight group.And there was significant difference between groups ( t =2.83, P <0.05 ).The clinical duration was (68.4 ±9.6) min in obese group versus (62.0 ±6.5) min in normal weight group.And there was significant difference between groups (t=2.33, P<0.05).The recovery index was (15.6 ±4.7) min in obese group versus ( 10.8 ±4.2 ) min in normal weight group.And there was significant difference between groups (t=3.03, P<0.05).Also 75% recovery time was (83.9 ±11.5) min in obese group versus (73.0 ±9.2) min in normal weight group.And there was significant difference between groups (t=2.94, P<0.05).But no differences existed in intubation conditions.Conclusion When dosed according to real body weight , onset time of cisatracurium is shorter while clinical duration and recovery index are prolonged in morbidly obese patients compared with normal weight counterparts .